Related Experiment Video

Updated: Mar 24, 2026

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays
04:07

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays

Published on: February 24, 2023

2.4K

PARP Inhibitors for Recurrent Ovarian Carcinoma: Current Treatment Options and Future Perspectives

J Sehouli1, E I Braicu2, R Chekerov2

  • 1Universitätsklinikum Berlin Charité, Klinik für Gynäkologie, Charté Comprehensive Cancer Center (CCCC), Berlin.

Geburtshilfe Und Frauenheilkunde
|March 5, 2016
PubMed

Insights

Poly (ADP-ribose) polymerase (PARP) inhibitors represent a milestone in personalized ovarian cancer treatment. These drugs exploit DNA repairdeficiencies in tumor cells, increasing treatment efficacy when combined with other therapies.

Area of Science:

  • Oncology
  • Genetics
  • Pharmacology

Background:

  • Recurrent ovarian carcinoma presents a significant clinical challenge.
  • Personalized medicine approaches are crucial for improving patient outcomes.

Approach:

  • PARP inhibitors leverage the concept of "synthetic lethality" to target cancer cells.
  • This mechanism exploits differences in DNA repair pathways between healthy and cancerous cells.

Key Points:

  • Olaparib is a well-studied PARP inhibitor for high-grade serous ovarian carcinoma (HGSC).
  • Tumor cells with impaired DNA repair are particularly sensitive to PARP inhibitors.
  • Combining PARP inhibitors with other treatments may enhance their efficacy.

Conclusions:

  • PARP inhibitors are a significant advancement in the personalized treatment of recurrent ovarian cancer.
  • Further research into combination therapies holds promise for optimizing treatment strategies.
Keywords:
BRCAPARP inhibitorsmolecular pathwayovarian cancer

More Related Videos

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

12.9K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.1K

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.7K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.3K